The European Patent Office (EPO) has decided to grant a patent covering the use of CRISPR-Cas9 gene editing to the University of California, University of Vienna, and Emmanuelle Charpentier. More information is available here, in a press release from UC Berkeley. This patent will apply to 38 countries and covers the use of Cas9 for genetic engineering in all cell types. The in vitro success of the technology was first described in summer 2012, in a publication by IGI Executive Director Jennifer Doudna of UC Berkeley and Emmanuelle Charpentier, now at the Max Planck Institute for Infection Biology in Berlin.
“We are excited that this patent will issue based on the foundational research we published with Emmanuelle Charpentier and the rest of our team. We look forward to the continued applications of gene-editing technology to solve problems in human health and agriculture,” states Dr. Doudna.